

EXHIBIT E

**Rita Charles
BioMarin Pharmaceutical, Inc.
Intellectual Property
Biotechnology Specialist
11 Pimentel Court
Novato, Calif 94949**

1. The first step is to identify the problem or question that needs to be addressed. This involves understanding the context and the specific requirements of the task.

2. Next, it is important to gather relevant information and data. This can be done through research, consultation with experts, or by analyzing existing resources.

3. Once the information is gathered, the next step is to develop a plan or strategy. This involves breaking down the problem into smaller, manageable parts and determining the best approach to solve each part.

4. After the plan is developed, the next step is to implement the solution. This involves putting the plan into action and monitoring the progress to ensure that the solution is effective.

5. Finally, it is important to evaluate the results of the solution. This involves comparing the actual outcomes with the expected results and identifying any areas for improvement.

371 Bel Marin Keys Boulevard
Suite 210 • Novato, CA 94949

703 HAT 1A0 038895 22 MAY MAIL INSIDE
WWW.PCS 256X375 PB AFTER COMPTON
WWW.CANADIAN 256X375 CANADIAN

ସ୍ଥଳ ପଥ

BIOMARIN
PHARMACEUTICAL INC

August 29, 2003

Brigitte Groulx
c/o Biochem Pharma
Cancer Biology Dept.
275 Armand Frappier
Laval, QC H7V 4A7
Tel: 450-978-7903

*Left Shire Biochem
May 2001*

Re: U.S. Patent Application No. 08/722,659
Title: Use of Heparinase to Decrease Inflammatory
Response
Inventors: Bennett *et al.*
Filed: September 27, 1996
Our reference No.: 104385.140

Dear Brigitte,

In furtherance of our prosecution of the above named patent, please sign the enclosed Declaration in blue ink and return it to me as soon as possible.

A return envelope is provided for your convenience.

If you have any questions regarding your Declaration or the present proceedings in the U.S. Patent and Trademark Office, please feel free to contact me directly at 415-884-6709 or lbigornia@bmrn.com.

Sincerely,



Luisa Bigornia Ph.D., Esq.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
BENNETT <i>et al.</i>)	Group Art Unit: 1644
)	
Serial No.: 08/722,659)	Examiner: A. DeCloux
)	
Filed: September 27, 1996)	
)	
For: USE OF HEPARINASE TO DECREASE INFLAMMATORY RESPONSE		

Commissioner for Patents
Washington, D.C. 20231

**DECLARATION UNDER 37 C.F.R. § 1.132
OF BRIGETTE GROUX**

I, Brigitte Grouix, do hereby declare that:

1. I am a joint inventor of the subject matter claimed in the above-identified application, along with Elizabeth Cauchon, Dominique Fink, Ariane Hsia, Joseph Zimmermann, D. Clark Bennett, and Pamela Danagher.
2. I am informed and believe that U.S. Patent No. 5,997,863 ("the '863 patent"), a copy of which is attached as Exhibit A, has been cited against the claims of the above-identified application. In particular, I am informed and believe that Example 8 found at col. 17, line 63-col. 18, line 29 has been cited against the above-captioned application in a prior art rejection.
3. While I am a co-inventor of the above-captioned application, I did not make an inventive contribution to the subject matter recited in paragraph 2. In particular, I was not involved in the animal model work described in Example 8 involving the local administration of heparinase to enhance revascularization, described generally at col. 17, line 63-col. 18, line 29.
4. The undersigned declares further that all statements made herein of my own

knowledge are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing therefrom.

Signed at _____

this __ day of _____, 2003.

Brigette Grouix



Luisa Bigornia

BIOMARIN

PHARMACEUTICAL INC

371 Bel Marin Keys Boulevard
Suite 210 • Novato, CA 94949


Ariane Hsia
c/o RIV LTD.
22 West
Toronto,



MOVED / UNKNOWN // DEMENAGE / INCONNU
RETURN TO SENDER
RENOI A L'EXPEDITEUR
CA 94949
USA



00101/3



BIOMARIN[™]

PHARMACEUTICAL INC

August 29, 2003

Ariane Hsia
c/o RIV LTD.
22 Wesllesley St. East
Toronto, Ontario
M4Y 1Y3

Re: U.S. Patent Application No. 08/722,659
Title: Use of Heparinase to Decrease Inflammatory
Response
Inventors: Bennett *et al.*
Filed: September 27, 1996
Our reference No.: 104385.140


Dear Ariane,

In furtherance of our prosecution of the above named patent, please sign the enclosed Declaration in blue ink and return it to me as soon as possible.

A return envelope is provided for your convenience.

If you have any questions regarding your Declaration or the present proceedings in the U.S. Patent and Trademark Office, please feel free to contact me directly at 415-884-6709 or lbigornia@bmrn.com.

Sincerely,



Luisa Bigornia Ph.D., Esq.

LSB/rvc

Attorney Docket No. 104385.140

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
BENNETT <i>et al.</i>)	Group Art Unit: 1644
)	
Serial No.: 08/722,659)	Examiner: A. DeCloux
)	
Filed: September 27, 1996)	
)	
For: USE OF HEPARINASE TO DECREASE INFLAMMATORY RESPONSE)	

Commissioner for Patents
Washington, D.C. 20231

**DECLARATION UNDER 37 C.F.R. § 1.132
OF ARIANE HSIA**

I, Ariane Hsia, do hereby declare that:

1. I am a joint inventor of the subject matter claimed in the above-identified application, along with Elizabeth Cauchon, Dominique Fink, Brigitte Grouix, Joseph Zimmermann, D. Clark Bennett, and Pamela Danagher.

2. I am informed and believe that U.S. Patent No. 5,997,863 ("the '863 patent"), a copy of which is attached as Exhibit A, has been cited against the claims of the above-identified application. In particular, I am informed and believe that Example 8 found at col. 17, line 63-col. 18, line 29 has been cited against the above-captioned application in a prior art rejection.

3. While I am a co-inventor of the above-captioned application, I did not make an inventive contribution to the subject matter recited in paragraph 2. In particular, I was not involved in the animal model work described in Example 8 involving the local administration of heparinase to enhance revascularization, described generally at col. 17, line 63-col. 18, line 29.

4. The undersigned declares further that all statements made herein of my own

knowledge are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing therefrom.

Signed at _____


this __ day of _____, 2003.

Ariane Hsia


371 Bel Marin Keys Boulevard
Suite 210 • Novato, CA 94949

Air Mail Par avion

Rita Charles
BioMarin Pharmaceutical, Inc.
Intellectual Property
Biotechnology Specialist
11 Pimentel Court
Novato, Calif 94949



103 H41 01.60309.0
15 MAY 2005
POSTAL
16335060309.0

[illegible]

U 43

BIOMARIN
PHARMACEUTICAL INC

August 29, 2003

Ms. Dominique Fink
4632 rue Chambord
Montreal, Quebec
H2J 3M7

Re: U.S. Patent Application No. 08/722,659
Title: Use of Heparinase to Decrease Inflammatory
Response
Inventors: Bennett *et al.*
Filed: September 27, 1996
Our reference No.: 104385.140

Dear Ms. Fink,

In furtherance of our prosecution of the above named patent, please sign the enclosed Declaration in blue ink and return it to me as soon as possible.

A return envelope is provided for your convenience.

If you have any questions regarding your Declaration or the present proceedings in the U.S. Patent and Trademark Office, please feel free to contact me directly at 415-884-6709 or lbigornia@bmrn.com.

Sincerely,



Luisa Bigornia Ph.D., Esq.

LSB/rvc

Attorney Docket No. 104385.140

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
BENNETT <i>et al.</i>)	Group Art Unit: 1644
)	
Serial No.: 08/722,659)	Examiner: A. DeCloux
)	
Filed: September 27, 1996)	
)	
For: USE OF HEPARINASE TO DECREASE INFLAMMATORY RESPONSE		

Commissioner for Patents
Washington, D.C. 20231

**DECLARATION UNDER 37 C.F.R. § 1.132
OF DOMINIQUE FINK**

I, Dominique Fink, do hereby declare that:

1. I am a joint inventor of the subject matter claimed in the above-identified application, along with Elizabeth Cauchon, Brigitte Grouix, Ariane Hsia, Joseph Zimmermann, D. Clark Bennett, and Pamela Danagher.
2. I am informed and believe that U.S. Patent No. 5,997,863 ("the '863 patent"), a copy of which is attached as Exhibit A, has been cited against the claims of the above-identified application. In particular, I am informed and believe that Example 8 found at col. 17, line 63-col. 18, line 29 has been cited against the above-captioned application in a prior art rejection.
3. While I am a co-inventor of the above-captioned application, I did not make an inventive contribution to the subject matter recited in paragraph 2. In particular, I was not involved in the animal model work described in Example 8 involving the local administration of heparinase to enhance revascularization, described generally at col. 17, line 63-col. 18, line 29.
4. The undersigned declares further that all statements made herein of my own

knowledge are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing therefrom.

Signed at _____

this __ day of _____, 2003.

Dominique Fink

BIOMARIN
P H A R M A C E U T I C A L I N C

047

August 29, 2003

Ms. Dominique Fink
4632 rue Chambord
Montreal, Quebec
H2J 3M7

Re: U.S. Patent Application No. 08/722,659
Title: Use of Heparinase to Decrease Inflammatory
Response
Inventors: Bennett *et al.*
Filed: September 27, 1996
Our reference No.: 104385.140

Dear Ms. Fink,

In furtherance of our prosecution of the above named patent, please sign the enclosed Declaration in blue ink and return it to me as soon as possible.

A return envelope is provided for your convenience.

If you have any questions regarding your Declaration or the present proceedings in the U.S. Patent and Trademark Office, please feel free to contact me directly at 415-884-6709 or lbigornia@bmrn.com.

Sincerely,

Luisa Bigornia Ph.D., Esq.

LSB/rvc